Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Safety and Efficacy of Switching to Alternative Biologics Following Secukinumab Treatment Failure in Patients with Moderate-to-Severe Plaque Psoriasis: A Retrospective Cohort Analysis

  • By

  • Zhongyu Zhang

  • Bin Zhang

  • Yating Wen

  • Qian Hu

  • Wenjun Jiang

  • Jia Zhuo

  • Guangying Luo

  • Yuyi Wang

  • July 6, 2026

Share

  • 1

    The study evaluated the safety and efficacy of switching to ixekizumab, guselkumab, or ustekinumab after secukinumab failure in 59 patients.

  • 2

    Ixekizumab showed significantly higher PASI 75 response rates at week 12 compared to guselkumab and ustekinumab, with rates of 66.7%, 28.1%, and 16.7%, respectively.

  • 3

    In the secondary failure subgroup, ixekizumab demonstrated a numerical advantage in PASI 75 response rates at all time points, though not statistically significant.

  • 4

    Adverse event rates were similar among the three biologics, with all events being mild and not requiring treatment discontinuation.

  • 5

    The choice of switching strategy should consider the type of treatment failure, patient preference, and specific drug characteristics.

Original Source(s)

Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study

  • by Zhongyu Zhang, Bin Zhang, Yating Wen, Qian Hu, Wenjun Jiang, Jia Zhuo, Guangying Luo, Yuyi Wang

  • July 6, 2026

Related Content

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study